Summit Therapeutics' Mixed Results and Market Impact in Oncology Trials
A Phase 3 trial of the drug ivonescimab, which targets PD-1 and VEGF pathways, showed it delayed tumor progression in lung cancer patients but did not significantly extend survival, potentially complicating its path to FDA approval in the US. The results highlight the challenges of demonstrating survival benefits for cancer drugs, despite promising progression-free survival data.